Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 1/20 | 0.36 |
| ▸ | DRD1 | P21728 | 1/20 | 0.35 |
| ▸ | CDK1 | P06493 | 1/20 | 0.30 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20194 | 0.79 | ENPP2 (0.50) | ENPP2 | |
| SCHEMBL17290670 | 0.75 | — | — | |
| SCHEMBL486856 | 0.74 | HTR6 (0.52) | DRD1CDK1CDK2KDR | |
| SCHEMBL486841 | 0.74 | HTR6 (0.52) | DRD1CDK1CDK2KDR | |
| SCHEMBL486787 | 0.74 | HTR6 (0.52) | DRD1CDK1CDK2KDR | |
| SCHEMBL23356361 | 0.73 | DRD1 (0.32) | ENPP2DRD1 | |
| SCHEMBL2377334 | 0.73 | — | — | |
| SCHEMBL818508 | 0.73 | HTR6 (0.50) | — | |
| SCHEMBL22116923 | 0.72 | HTR6 (0.50) | DRD1CDK1CDK2KDR | |
| SCHEMBL488382 | 0.72 | GAA (0.59) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4216946-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Achillion Pharmaceuticals, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| US-10723704-B2 | Pyrazolone derivatives as nitroxyl donors | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-20180318308-A1 | PYRAZOLONE DERIVATIVES AS NITROXYL DONORS | CARDIOXYL PHARMACEUTICALS, INC. | 2018-11-08 | — | — | US | disclosed |
| EP-3365328-A1 | PYRAZOLONE DERIVATIVES AS NITROXYL DONORS | Cardioxyl Pharmaceuticals, Inc. (US) | 2018-08-29 | — | — | EP | disclosed |
| US-9682938-B2 | Pyrazolone derivatives as nitroxyl donors | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| WO-2017070081-A1 | PYRAZOLONE DERIVATIVES AS NITROXYL DONORS | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2017-04-27 | — | — | WO | disclosed |
| EP-3148972-A1 | PYRAZOLONE DERIVATIVES AS NITROXYL DONORS | Cardioxyl Pharmaceuticals Inc. (US) | 2017-04-05 | — | — | EP | disclosed |
| WO-2015183839-A1 | PYRAZOLONE DERIVATIVES AS NITROXYL DONORS | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2015-12-03 | — | — | WO | disclosed |
| US-20150344437-A1 | PYRAZOLONE DERIVATIVES AS NITROXYL DONORS | THE JOHNS HOPKINS UNIVERSITY | 2015-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10723704-B2 | Pyrazolone derivatives as nitroxyl donors | TNNI3, PFKP, NOX5 | ENPP2 1306/4885DRD1 3778/4885CDK1 2760/4885 |
| US-20150344437-A1 | PYRAZOLONE DERIVATIVES AS NITROXYL DONORS | TNNI3, PFKP, NOX5 | ENPP2 1306/4885DRD1 3778/4885CDK1 2760/4885 |
| US-20180318308-A1 | PYRAZOLONE DERIVATIVES AS NITROXYL DONORS | TNNI3, PFKP, NOX5 | ENPP2 1306/4885DRD1 3778/4885CDK1 2760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.